The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
Background: The clinical experience with protease-inhibitor (PI) triple regimen appears disappointing regarding effect, side effects, high work load, and costs. This real-world study evaluates baseline and emerging resistance-associated substitutions (RASs) and their significance for treatment outco...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Upsala Medical Society
2018-01-01
|
| Серии: | Upsala Journal of Medical Sciences |
| Предметы: | |
| Online-ссылка: | http://dx.doi.org/10.1080/03009734.2018.1441928 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|